Foreign Institutional Investors (FIIs) are entities like mutual funds, pension funds, insurance companies, and investment trusts from outside India that invest in Indian financial markets. They play a crucial role in the Indian market by bringing in capital, liquidity, and global investment perspectives. Their investments help in boosting market sentiment, promote economic growth, and improve the overall stability of the financial markets. When FIIs invest in a stock, it signals confidence in the company’s growth prospects and the broader market. Their involvement can lead to increased stock prices due to the influx of funds and can also encourage domestic investors to follow suit. FIIs contribute significantly to market efficiency and corporate governance improvements.
2 Companies in which FII has bought a stake are:
Tourism Finance Corporation of India Ltd
Share Price
The shares of the company are currently trading at Rs. 139.81 up by 0.55% from its previous close of Rs. 139.04 as of February 04, 2025.
Stake Purchase
NECTA BLOOM VCC, a Singapore-based Variable Capital Company, has purchased 5.10 lakh equity shares of a company from the open market. The shares were acquired at a price of ₹143.41 per share, with the total transaction valued at ₹7.32 crore. This move reflects the FII’s confidence in the company and its potential for growth, while also adding to the liquidity and investor interest in the stock.
About the Company
Tourism Finance Corporation of India Ltd (TFCI) is a key financial institution that supports the growth of the tourism sector in India. It provides financial assistance to a variety of tourism-related projects, including hotels, resorts, restaurants, amusement parks, ropeways, and multiplexes. TFCI primarily offers long-term loans and also invests in debentures, equity, and preference shares of tourism companies. By providing essential funding, TFCI plays a vital role in promoting infrastructure development within the tourism industry, thereby contributing to economic growth and enhancing India’s tourism landscape.
Valiant Labs
Share Price
The shares of Valiant Laboratories Limited are currently trading at Rs. 100 up by 1.64% from its previous close of Rs. 98.38 as of February 4, 2025.
Stake Purchase
On January 31, 2025, NECTA BLOOM VCC further, made a bulk purchase of 275,000 equity shares at an average price of ₹102.75 per share on the NSE. The total value of this transaction amounts to ₹2.81 crore (275,000 x ₹102.75).
Simultaneously, MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITED executed a bulk sale of the same quantity at the same price, indicating a transfer of shares between parties. The absence of intraday trading suggests a long-term investment strategy, and the transaction reflects confidence in the company’s prospects.
About the Company
Incorporated in 1980, Valiant Laboratories Ltd (VLL) is a leading player in the pharmaceutical and specialty chemicals industry. The company specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs), particularly Paracetamol, which is widely used in various forms such as tablets, capsules, and other medications. VLL’s expertise in API production ensures high-quality products, meeting both domestic and international demand, and supporting the healthcare sector with critical over-the-counter medications.
Written By: Dipangshu Kundu
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
